Here’s the strange part of this story. GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are actually doing what they promised. People are losing weight, managing diabetes better, and seeing real health improvements. And that success is becoming a financial headache for the companies paying for it.
A new survey found that 14% of employers have already dropped GLP-1 coverage or plan to soon, according to reporting via KCAU9. The share of employers covering weight-loss drugs has fallen from 72% in 2025 to 60% in 2026. That’s a steep drop in just one year.
The numbers behind the squeeze
Pharmacy costs are expected to rise 12% for employers next year. Prescription drugs now account for roughly 25% of overall health care spending, and GLP-1s are a huge part of why.
Employer-sponsored health insurance is projected to surpass $18,500 per worker in 2026. That’s a 6.7% jump from 2025, according to Mercer’s data reported by SHRM, and it’s the largest year-over-year increase in 15 years.
If employers make no changes to their current plans at all, that overall increase would climb closer to 9%. GLP-1s alone are now estimated to account for 14% of all prescription drug spending in 2026, and that’s before counting direct-to-consumer sales that bypass insurance entirely.
The drugs themselves aren’t cheap to begin with. Brand-name injectables typically run $1,000 to $1,500 a month per patient, and employers often cover 70% to 100% of that cost.
Real employers, real sticker shock
The Peterson-KFF Health System Tracker interviewed employers directly, and the quotes say more than any statistic could.
One benefits administrator put it simply: GLP-1s went from the 32nd highest pharmacy expense one year to the single highest the very next year. A compensation manager at a large retail firm said their company spent half a million dollars on the drugs, then projected that number would balloon to $1.2 million the following year.
That kind of jump forces hard conversations. Some employers have raised co-pays for the first time in years. Others are adding stricter case management requirements or reconsidering coverage altogether.
It’s not all bad news, though
Here’s where the story gets more complicated than “drugs bad, costs up.” Aon analyzed claims data from 192,000 GLP-1 users and found something worth noting: users saw medical cost growth slow to just 3% over 18 months, compared to 9% for a control group not on the drugs, according to HFMA’s coverage of the findings.
Obesity contributes to more than 60 chronic conditions and drives 66% higher annual health care costs for people affected by it. It also costs the broader U.S. economy up to $1.72 trillion a year. So there’s a real argument that covering these drugs now could save money down the road, especially on cancer and other major cost drivers employers already worry about.
The catch is that “down the road” doesn’t help a CFO looking at next year’s budget. Long-term savings are a bet. This year’s premium increase is a certainty.
Why employers feel stuck either way
Cutting GLP-1 coverage isn’t a simple fix either. Benefits packages have become one of the main ways companies compete for talent, especially in a tight labor market. Stripping a benefit that employees have started to expect risks hurting retention and recruiting, even if it helps the budget in the short term.
And GLP-1s aren’t happening in a vacuum. They’re part of a broader wave of expensive specialty drugs, including cancer treatments, autoimmune therapies, and gene therapies that can cost over $500,000 per treatment. Employers are getting squeezed from multiple directions at once, and GLP-1s just happen to be the most visible, most talked-about piece of it.
There’s also a persistence problem worth mentioning. Data from Prime Therapeutics shows only 1 in 12 patients remain on GLP-1 treatment after three years. Employers are paying a premium for a drug that a lot of patients don’t end up sticking with long term, which makes the return on that investment even harder to predict.
What this means going forward
Expect this tug-of-war to keep playing out through 2026 and beyond. Some employers will keep cutting or restricting coverage. Others will hold the line, betting that long-term health savings and employee retention are worth the short-term cost.
Either way, if you get health insurance through your job and you’re on or considering a GLP-1 medication, it’s worth checking your plan’s coverage details now rather than waiting for open enrollment to surprise you. For more coverage on how health care costs are shifting in 2026, visit our health section.
